News and Events

Event banner for The Biology & Biophysics of the Nucleus Symposium

Biology & Biophysics of the Nucleus Symposium - October 20-21, 2022

The mission of the Center of Excellence in Chromosome Biology (CECB) is to achieve a comprehensive understanding of the mechanisms involved in chromosome function, how aberrations in chromosomes and chromatin lead to disease and how these defects can be corrected.

Towards achieving the mission, the Biology & Biophysics of the Nucleus Symposium brings together scientists in the fields of chromatin and chromosome biology, with the focus on stem cells, cell development, aging and cancer.

We hope this symposium offers you an opportunity to learn more about the current status of chromosome structure and function in development and disease, to share your research and to discuss the use and implications of these advances for clinical applications.

Organized by: Shalini Oberdoerffer, Ph.D., Gordon Hager, Ph.D., and Dave Levens, M.D., Ph.D.

Clinical trial researching therapy for bile duct cancer

A clinical trial led by Jonathan Hernandez, M.D., Investigator in the Surgical Oncology Program, is researching a combination of immunotherapy and chemotherapy for liver-only cholangiocarcinoma.

The middle portion of the gastrointestinal tract is a common location for cancerous neuroendocrine tumors to form.

Clinical trial evaluates drug combination for inoperable neuroendocrine tumors

Neuroendocrine tumors occur in cells of the endocrine and nervous systems. A combined phase I/II clinical trial at the NIH Clinical Center evaluates the effectiveness of a combination of two agents that may work in complementary ways to target inoperable or metastatic neuroendocrine tumors.

image of female physician using a stethoscope on a young female patient

Clinical trial researching T-cell therapy for sarcoma

John W. Glod, M.D., Ph.D., Associate Research Physician in the Pediatric Oncology Branch, is leading NCI’s participation in a clinical trial researching T-cell therapy for sarcomas.

Three-dimensional illustration of a T cell attacking a cancer cell.

T-cell imbalance can impact immunotherapy outcomes

The rapid growth of a patient’s cancer following immune checkpoint inhibitor therapy, known as hyperprogressive disease, is an unexpected treatment outcome that is challenging to predict or study. New results show that a T-cell imbalance in the tumor microenvironment can trigger the condition.

A spheroid of breast cancer cells grown in a three-dimensional matrix.

Mapping cells’ mechanical properties for insight into metastasis

A new approach allows researchers to investigate cells’ mechanical properties in tissue-like environments.

Clinical trial researching therapy for tumors that have spread to the lining of the abdomen

A clinical trial led by Andrew M. Blakely, M.D., Assistant Research Physician in the Surgical Oncology Program, is researching a combination drug therapy for peritoneal carcinomatosis, a condition in which tumors have spread along the lining of the abdomen from the appendix, colon, ovary or mesothelioma.

Clinical trial researches drug therapy for bone marrow neoplasms

A clinical trial led by Steven Z. Pavletic, M.D., Senior Clinician in the Immune Deficiency Cellular Therapy Program, is researching a therapy for myelodysplastic syndromes (MDS), a group of bone marrow neoplasms.

Scan of bone marrow from mice with non-alcoholic fatty liver disease

Liver cancer may unexpectedly be influenced by platelets

Platelets have long been associated with more aggressive cancers; however, new results show that these cell fragments release molecules with anti-tumor properties against liver cancer, reducing tumor burden in mice. The results provide detailed insights into the mysterious role of platelets in cancer progression.

Clinical trial researching therapy for prostate cancer

A clinical trial led by Ravi A. Madan, M.D., Senior Clinician in the Genitourinary Malignancies Branch, is researching a combination drug therapy for prostate cancer.

Breadcrumb